Summary
20 / 100 · Bulios Score
What speaks for it
- Analysts expect revenue to grow by 18% this fiscal year.
- It bought back its own shares for ¥2.53B in the last fiscal year, 3.5% of its market value.
What to watch
- Revenue fell by 13% a year over the last 3 years.
- Repaying its net debt would take 10.5 years of operating profit.
- It pays out more in dividends than it earns: 282% of profit.
- The share price is above the Bulios Fair Price.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 83.1 JPY for 1 JPY of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (JPY)
Diluted EPS (JPY)
- Analyst estimate
Revenue grew by 5.9% a year over 5 years. Over the last 3 years it fell by 13% a year. For the next fiscal year analysts expect revenue to grow by 18%.
Growth in detailDoes it make money?
PoorlyWhere 100 JPY of revenue goes
- Cost of sales 24 JPY
- Research and development 46 JPY
- Sales and administration 31 JPY
- Taxes and other -4.4 JPY
- Net profit 2.1 JPY
Net profit, industry median (Drug Manufacturers - General) 14 JPY
Out of every 100 JPY of revenue, 2.1 JPY is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenIts debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Moderate, at risk- Yield
- 3.39%
- Paid out of profit
- 282%
You receive $0.13 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.